SUSVIMO is a prescription medicine used to treat adults with neovascular (wet) Age‐related Macular Degeneration (AMD) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).

6 days ago · Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to U.S. retina specialists and their patients with DME.

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.

Find information about Genentech's Susvimo® (ranibizumab injection), including clinical trials, scientific congress posters and presentations, and publications.

6 days ago · FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness. Business Wire . Tue, Feb 4, 2025, 11:45 AM 11 min read.

Learn about SUSVIMO® (ranibizumab injection), a treatment option for wet age-related macular degeneration (wet AMD). See Full Safety and Boxed Warning for more information. SUSVIMO: now available for the treatment of diabetic macular edema (DME) .

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.

Feb 4, 2025 · Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) 100 mg/mL for ...

Jul 23, 2024 · Genentech, a member of the Roche Group, announced 2-year data from the Phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively.

Oct 22, 2021 · Susvimo, previously called Port Delivery System with ranibizumab, is the first wet AMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a month.